PremiumThe FlyHutchmed/Innovent update on Phase 2/3 study of Fruquintinib+Sintilimab Hutchmed completes enrollment of fanregratinib trial HUTCHMED Updates on Major Divestment in Shanghai Hutchison Pharmaceuticals PremiumThe FlyHutchmed announces NDA acceptance in China, payment from AstraZeneca Hutchmed divests 45% interest in Shanghai Hutchison for $608M Hutchmed to receive milestone payment from Takeda PremiumThe FlyHutchmed to receive $20M milestone payment from Takeda for Fruzaqla sales Hutchmed announces results from SAVANNAH trial Hutchmed, Takeda receive Japan MHLW approval to manufacture and market Fruzaqla 
